When Should You Buy Reckon Limited (ASX:RKN)?

Reckon Limited (ASX:RKN), which is in the software business, and is based in Australia, saw a decent share price growth in the teens level on the ASX over the last few months. Less-covered, small caps sees more of an opportunity for mispricing due to the lack of information available to the public, which can be a good thing. So, could the stock still be trading at a low price relative to its actual value? Today I will analyse the most recent data on Reckon’s outlook and valuation to see if the opportunity still exists.

View our latest analysis for Reckon

Advertisement

What's the opportunity in Reckon?

Good news, investors! Reckon is still a bargain right now. According to my valuation, the intrinsic value for the stock is A$1.17, which is above what the market is valuing the company at the moment. This indicates a potential opportunity to buy low. Reckon’s share price also seems relatively stable compared to the rest of the market, as indicated by its low beta. If you believe the share price should eventually reach its true value, a low beta could suggest it is unlikely to rapidly do so anytime soon, and once it’s there, it may be hard to fall back down into an attractive buying range.

Can we expect growth from Reckon?

ASX:RKN Past and Future Earnings, December 25th 2019
ASX:RKN Past and Future Earnings, December 25th 2019

Investors looking for growth in their portfolio may want to consider the prospects of a company before buying its shares. Buying a great company with a robust outlook at a cheap price is always a good investment, so let’s also take a look at the company's future expectations. Though in the case of Reckon, it is expected to deliver a relatively unexciting earnings growth of 4.0%, which doesn’t help build up its investment thesis. Growth doesn’t appear to be a main reason for a buy decision for the company, at least in the near term.

What this means for you:

Are you a shareholder? Even though growth is relatively muted, since RKN is currently undervalued, it may be a great time to accumulate more of your holdings in the stock. However, there are also other factors such as financial health to consider, which could explain the current undervaluation.

Are you a potential investor? If you’ve been keeping an eye on RKN for a while, now might be the time to enter the stock. Its future outlook isn’t fully reflected in the current share price yet, which means it’s not too late to buy RKN. But before you make any investment decisions, consider other factors such as the strength of its balance sheet, in order to make a well-informed investment decision.

Price is just the tip of the iceberg. Dig deeper into what truly matters – the fundamentals – before you make a decision on Reckon. You can find everything you need to know about Reckon in the latest infographic research report. If you are no longer interested in Reckon, you can use our free platform to see my list of over 50 other stocks with a high growth potential.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.

About ASX:RKN

Reckon

Provides software solutions in Australia, New Zealand, the United States, and internationally.

Undervalued with solid track record.

Advertisement

Weekly Picks

ST
stuart_roberts
UNCY logo
stuart_roberts on Unicycive Therapeutics ·

Looking to be second time lucky with a game-changing new product

Fair Value:US$21.5370.8% undervalued
60 users have followed this narrative
0 users have commented on this narrative
9 users have liked this narrative
HE
PLY logo
HegelBayeBagel on PlaySide Studios ·

PlaySide Studios: Market Is Sleeping on a Potential 10M+ Unit Breakout Year, FY26 Could Be the Rerate of the Decade

Fair Value:AU$0.8460.7% undervalued
12 users have followed this narrative
2 users have commented on this narrative
7 users have liked this narrative
AN
AnimalDoctorKwon
NOTV logo
AnimalDoctorKwon on Inotiv ·

Inotiv NAMs Test Center

Fair Value:US$1.278.3% undervalued
20 users have followed this narrative
2 users have commented on this narrative
6 users have liked this narrative
TH
CGNT logo
TheValueDetector on Cognyte Software ·

This isn’t speculation — this is confirmation.A Schedule 13G was filed, not a 13D, meaning this is passive institutional capital, not acti

Fair Value:US$95.6792.9% undervalued
41 users have followed this narrative
2 users have commented on this narrative
7 users have liked this narrative

Updated Narratives

JA
KO logo
Jades on Coca-Cola ·

Coca-Cola’s Enduring Moat in a Health-Conscious World: Steady Compounder Poised for 5-10% Annual Returns Through Emerging Market Dominance

Fair Value:US$66.220.6% overvalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
BR
MAR logo
Bradleywang on Marriott International ·

Asset-Light but Valuation-Heavy: A Fundamental Breakdown of Marriott ($MAR)

Fair Value:US$313.9410.8% overvalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
CT
NOVO B logo
ctmlin910 on Novo Nordisk ·

Why did Novo Nordisk flop?

Fair Value:DKK 2874.9% overvalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

DA
davidlsander
UBI logo
davidlsander on Ubisoft Entertainment ·

Is Ubisoft the Market’s Biggest Pricing Error? Why Forensic Value Points to €33 Per Share

Fair Value:€33.887.9% undervalued
61 users have followed this narrative
5 users have commented on this narrative
27 users have liked this narrative
AN
AnalystConsensusTarget
MSFT logo
AnalystConsensusTarget on Microsoft ·

Analyst Commentary Highlights Microsoft AI Momentum and Upward Valuation Amid Growth and Competitive Risks

Fair Value:US$59633.4% undervalued
1294 users have followed this narrative
2 users have commented on this narrative
9 users have liked this narrative
TA
Talos
TSLA logo
Talos on Tesla ·

The "Physical AI" Monopoly – A New Industrial Revolution

Fair Value:US$665.3638.1% undervalued
48 users have followed this narrative
19 users have commented on this narrative
22 users have liked this narrative
Advertisement